IVD Classification under Schedule 1 Part 2 in Canada

1. Key takeaways

The classification of in vitro diagnostic devices (IVDs) follows the rules of Part 2 of Schedule 1 of the Medical Devices Regulations, and those rules are not mixed with Part 1, which governs non-IVD devices. Performance evidence for an IVD is typically built from two parts: analytical performance (precision, detection limit, linearity, interference and stability) and clinical concordance (comparison against a comparative method or against clinical diagnosis). Near-patient IVDs that fall into Class III carry a separate fee item (30,169 Canadian dollars). Getting the Part determination right at the start prevents the most fundamental classification error; getting the near-patient determination right prevents the most consequential budget error.

• IVDs are classified under Schedule 1, Part 2 only; Part 1 applies to non-IVD devices.
• Performance evidence combines analytical performance and clinical concordance.
• Analytical performance covers precision, detection limit, linearity, interference and stability.
• Class III near-patient IVD applications carry a distinct fee of 30,169 Canadian dollars (from 2026-04-01).
• Class III and IV IVDs must also include clinical effectiveness evidence.
• IVDs sold to the general public require English and French bilingual information under section 23(3).

2. Legal basis

The table below consolidates the sources used in this article: the classification provisions of the Regulations, the Health Canada fee schedule for MDL application reviews, and the official device examples. All were verified against canada.ca or Justice Laws in 2026, with the fee figures taken from the published fee schedule.

3. Expert insights

Insight 1: IVD and non-IVD classification rules sit in two separate parts.

Under section 6 of the Medical Devices Regulations, Part 1 of Schedule 1 contains the classification rules for non-IVD devices and Part 2 contains the classification rules for in vitro diagnostic devices. Citing Part 1 rules for an IVD project is an error of application, not a stylistic slip: the Part 2 rules are written around the IVD risk logic, and a rationale built on Part 1 will not map onto the IVD questions the rules actually ask. The classification section of the dossier should therefore open by confirming the Part, then cite the specific Part 2 rule numbers and show how the device’s intended use and characteristics bring those rules into play. Reviewers read this section first to orient themselves, and a clean Part-and-rule statement sets the tone for the rest of the dossier.

Insight 2: near-patient IVDs are a separate line in the fee table, and the distinction drives the budget.

The Class III near-patient IVD application fee is 30,169 Canadian dollars (from 2026-04-01), notably higher than the 14,163 Canadian dollars for an ordinary Class III application and close to the 30,713 Canadian dollars for Class IV. Whether a device counts as a near-patient IVD therefore determines the order of magnitude of the application budget. Because the fee attaches to the classification and the near-patient determination together, both should be settled before budgeting, and the reasoning for the near-patient determination should be documented in the same file as the classification rationale. A project that discovers the near-patient status after budget approval faces an uncomfortable conversation that early analysis would have avoided entirely.

Insight 3: Class III and IV IVDs must also include clinical effectiveness evidence.

Health Canada attaches the clinical effectiveness evidence requirement to Class III and IV applications generally, and IVDs are no exception. For Class III and IV IVDs, the strength of the clinical concordance evidence — the comparison against a comparative method or clinical diagnosis — must match this requirement. In practice this means the concordance study design, the comparator, the sample set and the analysis plan should be planned with the clinical effectiveness requirement in view, not assembled afterwards from whatever concordance data happen to exist. For IVD projects the two evidence streams, analytical performance and clinical concordance, should be planned as one coordinated programme so that the dossier reads as a coherent demonstration of effectiveness rather than two unrelated data packages.

Insight 4: IVD classification and public-sale status together determine the labelling language requirement.

Public-facing IVDs such as pregnancy test kits must, under section 23(3), provide the information required by paragraphs 21(1)(a) and (e) to (j) in both English and French. For IVD projects this is the most expensive language scenario, because it applies to precisely the category of device that most often reaches consumers directly: self-tests, screening kits and monitoring products sold over the counter. The bilingual obligation covers a defined set of label paragraphs, which means the artwork, the outer packaging and the instructions for use all carry bilingual content for those paragraphs. Planning the bilingual versions as part of the label development — rather than as a translation task appended at the end — keeps the two language versions aligned in content and review status, and avoids the situation where the English and French versions of a public-facing label drift apart across product revisions.

4. Practical recommendations

• Cite Schedule 1 Part 2 rules for all IVD classifications and state the rule numbers.
• Determine whether the device falls into the near-patient IVD fee item and budget 30,169 Canadian dollars if applicable.
• Organise performance evidence in two parts: analytical performance and clinical concordance.
• Prepare clinical effectiveness evidence in step for Class III and IV IVDs.
• Apply English and French bilingual labelling under section 23(3) for public-facing IVDs and plan the bilingual instructions for use.

5. Verification checklist

• □ Classification has been completed citing Schedule 1 Part 2 rules.
• □ Whether the device falls into the near-patient IVD fee item has been determined and the budget adjusted accordingly.
• □ Analytical performance evidence is complete (precision, detection limit, linearity, interference, stability).
• □ Clinical concordance evidence is complete.
• □ Clinical effectiveness evidence is in place for Class III and IV IVDs.
• □ Public-facing IVDs carry bilingual labelling completed under section 23(3).

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com